GlaxoSmithKline announces the final analysis of the efficacy trial of a cervical cancer vaccine. The study, involving 18,644 women, confirmed GlaxoSmithKline’s Cervarix is effective at protecting against the
King Pharmaceuticals and Pain Therapeutics have announced that on July 2, 2009, King met with the FDA to discuss the Complete Response Letter regarding the New Drug Application
Celgene has filed a New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare (MHLW) for Revlimid (lenalidomide) in combination with dexamethasone for the treatment
Kineta and Airmid have announced an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid. The array
Galapagos has successfully identified a second pre-clinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached a milestone on another compound in the alliance. Together
Pharmasset has nominated PSI-352938 (PSI-938) as a lead development candidate from two series of purine analogs, for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is
Essilor has extended its external growth strategy through a number of recent transactions in Europe, North America and the Middle East. The company has acquired all outstanding shares
Synergy Pharmaceuticals has completed the final tranche of its private placement. It raised gross proceeds of an aggregate $7.09 million through the sale of 10,132,143 shares of common
Repros Therapeutics provides a further update on the clinical development of Proellex 25mg and 12.5mg doses. Repros’ recent decision to discontinue the use of the Proellex 50mg dose
EMEA has agreed to an oral explanation in support of the Cell Therapeutics’ OPAXIO Marketing Authorization Application (MAA) in September 2009. It extended the review for the Committee
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.